The price and value of therapeutic synergy in liver cancer

David J Pinato¹, Antonio D'Alessio², Ciro Celsa³, Giulia F Manfredi⁴, Claudia A M Fulgenzi⁵

Affiliations

¹ Department of Surgery and Cancer, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London W12 0NN, UK; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy. Electronic address: david.pinato@imperial.ac.uk.
² Department of Surgery and Cancer, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London W12 0NN, UK; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
³ Department of Surgery and Cancer, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London W12 0NN, UK; Section of Gastroenterology and Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy; Department of Surgical, Oncological, and Oral Sciences, University of Palermo, Palermo, Italy.
⁴ Department of Surgery and Cancer, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London W12 0NN, UK; Division of Internal Medicine, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
⁵ Department of Surgery and Cancer, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London W12 0NN, UK; Department of Medical Oncology, University Campus Bio-Medico of Rome, Rome, Italy.

PMID: 37499669
DOI: 10.1016/S0140-6736(23)01297-7

Comment

The price and value of therapeutic synergy in liver cancer

David J Pinato et al. Lancet. 2023.

. 2023 Sep 30;402(10408):1108-1110.

doi: 10.1016/S0140-6736(23)01297-7. Epub 2023 Jul 24.

Authors

David J Pinato¹, Antonio D'Alessio², Ciro Celsa³, Giulia F Manfredi⁴, Claudia A M Fulgenzi⁵

Affiliations

¹ Department of Surgery and Cancer, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London W12 0NN, UK; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy. Electronic address: david.pinato@imperial.ac.uk.
² Department of Surgery and Cancer, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London W12 0NN, UK; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
³ Department of Surgery and Cancer, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London W12 0NN, UK; Section of Gastroenterology and Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy; Department of Surgical, Oncological, and Oral Sciences, University of Palermo, Palermo, Italy.
⁴ Department of Surgery and Cancer, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London W12 0NN, UK; Division of Internal Medicine, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
⁵ Department of Surgery and Cancer, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London W12 0NN, UK; Department of Medical Oncology, University Campus Bio-Medico of Rome, Rome, Italy.

PMID: 37499669
DOI: 10.1016/S0140-6736(23)01297-7

No abstract available

PubMed Disclaimer

Conflict of interest statement

DJP reports grants from GlaxoSmithKline, Bristol Myers Squibb, and Merck Sharp & Dohme for supporting academic trials in oncology; personal payment from Wiley for an Editor in Chief role unrelated to the topic of this Comment; consulting fees from Mina Therapeutics, EISAI, H3B, AstraZeneca, DaVolterra, Avamune, Bristol Myers Squibb, and Roche for supporting research in oncology unrelated to the topic of this Comment; speaker's fees from Roche, Bristol Myers Squibb, EISAI, and Ewopharma unrelated to the topic of this Comment; travel support from Merck Sharp & Dohme and Bayer; and participation on advisory boards for Astra Zeneca, EISAI, and H3B unrelated to the topic of this Comment. CC reports consulting fees from Eisai, Ipsen, and Merck Sharp & Dohme for supporting research in liver cancer unrelated to the topic of this Comment. All the other authors declare no competing interests.

Comment on

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The price and value of therapeutic synergy in liver cancer

Affiliations

The price and value of therapeutic synergy in liver cancer

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical